Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Arthritis and Rheumatism

Volumn 62, Issue 9, 2010, Pages 2625-2632

  Gottenberg, J E ^a   Ravaud, P ^b   Bardin, T ^c   Cacoub, P ^d   Cantagrel, A ^e   Combe, B ^f   Dougados, M ^g   Flipo, R M ^h   Godeau, B ⁱ   Guillevin, L ^g   Le Loet X ^j   Hachulla, E ^h   Schaeverbeke, T ^k   Sibilia, J ^a   Baron, G ^b   Mariette, X ^l  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

^f LAPEYRONIE HOSPITAL   (France)

^g Hôpital Cochin Assistance Publique Hôpitaux de Paris Université Paris Descartes ^*  (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CORTICOSTEROID; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BONE INFECTION; CHRONIC LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CORYNEBACTERIUM INFECTION; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; EYE INFECTION; FELTY SYNDROME; FEMALE; FOLLOW UP; FUNGEMIA; GASTROINTESTINAL INFECTION; HEART FAILURE; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; NOSE INFECTION; PHARYNGITIS; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SCLERITIS; SEPTICEMIA; SJOEGREN SYNDROME; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; URINARY TRACT INFECTION; AGAMMAGLOBULINEMIA; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; COMPLICATION; CONTRAINDICATIONS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; REGISTER; RISK FACTOR;

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956391149     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27555     Document Type: Article

References (21)

1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo- controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
4. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists [published erratum appears in Ann Rheum Dis 2007; 66:1548]. Ann Rheum Dis 2007;66:1339-44.
5. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
6. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
7. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova- Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52: 3403-12.
8. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66: 880-5. (Pubitemid 46999787)
9. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
10. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295: 2482]. JAMA 2006;295:2275-85.
11. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908. (Pubitemid 350262316)
12. Van Vollenhoven RF, Emery P, Bingham CO III, Keystone E, Fleischmann RM, Furst DE, et al. Long term safety of rituximab: follow-up of the RA clinical trials and re-treatment population [abstract]. Ann Rheum Dis 2009;68 Suppl 3:76.
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Van Vollenhoven RF, Chatzidionysiou K, Gabay C, Hetland ML, Tarp U, Gomez-Reino JJ, et al. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA) [abstract]. Ann Rheum Dis 2009;68 Suppl 3:579.
15. Strangfeld A, Hierse F, Listing J, Kekow J, Richter C, Tony HP, et al. RA patients treated with rituximab: routine care data of the German biologics register RABBIT [abstract]. Arthritis Rheum 2008;58 Suppl:S305.
16. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10: 816-24.
17. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;14:4834-40.
18. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008;67 Suppl 3:iii64-5.
19. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
20. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
21. Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009;39:18-29.